Addex Therapeutics Reported Q2 EPS Of CHF0.08, Cash Balance Of CHF3.8M

Benzinga09-30

Key Half Year and Q2 2024 Financial Data:

CHF' thousands	Q2 24	Q2 23*	Change	H1 24	H1 23*	Change
Income	115	632	(517)	350	1,134	(784)
R&D expenses	(339)	(291)	(48)	(584)	(547)	(37)
G&A expenses	(675)	(737)	62	(1,453)	(1,351)	(102)
Total operating loss	(899)	(396)	(503)	(1,687)	(764)	(923)
Finance result, net	(27)	(125)	98	26	(127)	153
Share of net loss of associates	(531)	-	(531)	(531)	-	(531)
Net loss from continuing operations	(1,457)	(521)	(936)	(2,192)	(891)	(1,301)
Net profit / (loss) from discontinued operations	14,336	(2,154)	16,490	11,983	(4,191)	16,174
Net profit / (loss) for the period	12,879	(2,675)	15,554	9,791	(5,082)	14,873
Basic net profit / (loss) per share	0.13	(0.04)	0.17	0.10	(0.08)	0.18
Diluted net profit / (loss) per share	0.08	(0.04)	0.12	0.06	(0.08)	0.14
Net increase / (decrease) in cash and cash equivalents	2,160	1,574	586	(77)	212	(289)
Cash and cash equivalents as of June 30	3,788	7,169	(3,381)	3,788	7,169	(3,381)
Shareholders' equity as of June 30	12,651	6,126	6,525	12,651	6,125	6,525

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2471252518?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-30 14:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2471252518","market":"us","top_or_hot":-1,"title":"Addex Therapeutics Reported Q2 EPS Of CHF0.08, Cash Balance Of CHF3.8M","media":"Benzinga","content":"<html><body><p><strong>Key Half Year and Q2 2024 Financial Data:</strong></p><figure><table><tbody><tr><td><strong>CHF' thousands</strong></td><td><strong>Q2 24</strong></td><td><strong>Q2 23*</strong></td><td><strong>Change</strong></td><td><strong>H1 24</strong></td><td><strong>H1 23*</strong></td><td><strong>Change</strong></td></tr><tr><td><strong>Income</strong></td><td><strong>115</strong></td><td><strong>632</strong></td><td><strong>(517)</strong></td><td><strong>350</strong></td><td><strong>1,134</strong></td><td><strong>(784)</strong></td></tr><tr><td>R&amp;D expenses</td><td>(339)</td><td>(291)</td><td>(48)</td><td>(584)</td><td>(547)</td><td>(37)</td></tr><tr><td>G&amp;A expenses</td><td>(675)</td><td>(737)</td><td>62</td><td>(1,453)</td><td>(1,351)</td><td>(102)</td></tr><tr><td><strong>Total operating loss</strong></td><td><strong>(899)</strong></td><td><strong>(396)</strong></td><td><strong>(503)</strong></td><td><strong>(1,687)</strong></td><td><strong>(764)</strong></td><td><strong>(923)</strong></td></tr><tr><td>Finance result, net</td><td>(27)</td><td>(125)</td><td>98</td><td>26</td><td>(127)</td><td>153</td></tr><tr><td>Share of net loss of associates</td><td>(531)</td><td>-</td><td>(531)</td><td>(531)</td><td>-</td><td>(531)</td></tr><tr><td><strong>Net loss from continuing operations</strong></td><td><strong>(1,457)</strong></td><td><strong>(521)</strong></td><td><strong>(936)</strong></td><td><strong>(2,192)</strong></td><td><strong>(891)</strong></td><td><strong>(1,301)</strong></td></tr><tr><td><strong>Net profit / (loss) from discontinued operations</strong></td><td><strong>14,336</strong></td><td><strong>(2,154)</strong></td><td><strong>16,490</strong></td><td><strong>11,983</strong></td><td><strong>(4,191)</strong></td><td><strong>16,174</strong></td></tr><tr><td><strong>Net profit / (loss) for the period</strong></td><td><strong>12,879</strong></td><td><strong>(2,675)</strong></td><td><strong>15,554</strong></td><td><strong>9,791</strong></td><td><strong>(5,082)</strong></td><td><strong>14,873</strong></td></tr><tr><td>Basic net profit / (loss) per share</td><td>0.13</td><td>(0.04)</td><td>0.17</td><td>0.10</td><td>(0.08)</td><td>0.18</td></tr><tr><td>Diluted net profit / (loss) per share</td><td>0.08</td><td>(0.04)</td><td>0.12</td><td>0.06</td><td>(0.08)</td><td>0.14</td></tr><tr><td>Net increase / (decrease) in cash and cash equivalents</td><td>2,160</td><td>1,574</td><td>586</td><td>(77)</td><td>212</td><td>(289)</td></tr><tr><td>Cash and cash equivalents as of June 30</td><td>3,788</td><td>7,169</td><td>(3,381)</td><td>3,788</td><td>7,169</td><td>(3,381)</td></tr><tr><td>Shareholders' equity as of June 30</td><td>12,651</td><td>6,126</td><td>6,525</td><td>12,651</td><td>6,125</td><td>6,525</td></tr></tbody></table></figure></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Addex Therapeutics Reported Q2 EPS Of CHF0.08, Cash Balance Of CHF3.8M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAddex Therapeutics Reported Q2 EPS Of CHF0.08, Cash Balance Of CHF3.8M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-30 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/24/09/41085229/addex-therapeutics-reported-q2-eps-of-chf0-08-cash-balance-of-chf3-8m><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Half Year and Q2 2024 Financial Data:CHF' thousandsQ2 24Q2 23*ChangeH1 24H1 23*ChangeIncome115632(517)3501,134(784)R&D expenses(339)(291)(48)(584)(547)(37)G&A expenses(675)(737)62(1,453)(1,351)(...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/24/09/41085229/addex-therapeutics-reported-q2-eps-of-chf0-08-cash-balance-of-chf3-8m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADXN","symbol_name":"Addex Therapeutics Ltd","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/24/09/41085229/addex-therapeutics-reported-q2-eps-of-chf0-08-cash-balance-of-chf3-8m","article_id":"2471252518","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2471252518","pubTimestamp":1727678974,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Key Half Year and Q2 2024 Financial Data:CHF&#39; thousandsQ2 24Q2 23*ChangeH1 24H1 23*ChangeIncome115632(517)3501,134(784)R&amp;D expenses(339)(291)(48)(584)(547)(37)G&amp;A","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ADXN":"Addex Therapeutics Ltd","LENZ":"Therapeutics"},"translate_title":"Addex Therapeutics报告第二季度每股收益为0.08瑞士法郎，现金余额为380万瑞士法郎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ADXN":0.9},"content_text":"Key Half Year and Q2 2024 Financial Data:CHF' thousandsQ2 24Q2 23*ChangeH1 24H1 23*ChangeIncome115632(517)3501,134(784)R&D expenses(339)(291)(48)(584)(547)(37)G&A expenses(675)(737)62(1,453)(1,351)(102)Total operating loss(899)(396)(503)(1,687)(764)(923)Finance result, net(27)(125)9826(127)153Share of net loss of associates(531)-(531)(531)-(531)Net loss from continuing operations(1,457)(521)(936)(2,192)(891)(1,301)Net profit / (loss) from discontinued operations14,336(2,154)16,49011,983(4,191)16,174Net profit / (loss) for the period12,879(2,675)15,5549,791(5,082)14,873Basic net profit / (loss) per share0.13(0.04)0.170.10(0.08)0.18Diluted net profit / (loss) per share0.08(0.04)0.120.06(0.08)0.14Net increase / (decrease) in cash and cash equivalents2,1601,574586(77)212(289)Cash and cash equivalents as of June 303,7887,169(3,381)3,7887,169(3,381)Shareholders' equity as of June 3012,6516,1266,52512,6516,1256,525","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2471252518"}